Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CNTB vs PYPD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNTB Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

CNTB Overall Winner 6-Pillar Tally: CNTB 4 – 1 PYPD (1 Tie) Matrix Metrics: CNTB 5 – 4 PYPD

As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNTB carries a Unified Composite Score of 41.0/100 (SELL) at $0.61 (0.8x Forward P/E, -2384.5% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both CNTB (41.0/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNTB vs PYPD
CNTB NASDAQ Head-to-Head Winner
Connect Biopharma Holdings Limited Ordinary Shares
Pharmaceutical Preparations
$0.61
-5.07% 1D
Market Cap $42.6M
TTM Revenue $3.0M
Forward P/E 0.8x
Beta / 30D Vol 0.92β · 68% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 25.0 Fund 48.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.7%), weak momentum, RSI 26
RSI-14: 25.6 · SMA20: $0.75 · SMA50: $0.99
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $5.81 · SMA50: $5.40

6-Pillar Scorecard Institutional Category Breakdown (CNTB 4 – 1 PYPD)

Columns: Metric · CNTB · PYPD
1. Valuation Multiples CNTB
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 5.5x N/M
2. Growth & Scale CNTB
Revenue Growth (YoY) +5666.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.0M N/A
Market Cap $42.6M $132.2M
3. Profitability & Quality CNTB
Gross Margin 100.0% N/A
Operating Margin -2384.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -140.5% -243.6%
4. Balance Sheet & Cash Flow CNTB
Cash Generation (TTM) -$61M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $5.0M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 397.3% (100th %ile) 106.3% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNTB (5) vs PYPD (4)
Institutional Metric CNTB PYPD Criterion Row Edge
Market Capitalization
Scale
$42.6M $132.2M Larger Scale PYPD
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple CNTB
Revenue Growth (YoY)
Growth
+5666.7% +0.0% Higher Growth CNTB
Operating Margin (TTM)
Profitability
-2384.5% 0.0% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-140.5% -243.6% Higher ROE CNTB
52-Week Range Position
Momentum
2% ($1–$4) 80% ($4–$7) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.92β · 68% Vol 0.89β · 59% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 31.1 / 100 (SELL) Higher Composite CNTB
Trailing 12M Revenue (USD)
Operating Scale
$3.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$61M ($26M Net Cash) N/A ($5.0M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +64.02 pp
CNTB: -32.16% · PYPD: +31.86%
3M Horizon PYPD +103.63 pp
CNTB: -75.19% · PYPD: +28.44%
6M Horizon PYPD +107.32 pp
CNTB: -72.13% · PYPD: +35.19%
1Y Horizon PYPD +150.46 pp
CNTB: -71.21% · PYPD: +79.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTB vs PYPD. Trailing 12-month operating profitability (CNTB -2384.5% vs PYPD 0.0%) and valuation multiples (CNTB 0.8x vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CNTB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.0M
Gross Margin100.0%
Op. Margin-2384.5%
ROE / Fwd P/E-140.5% · 0.8x
PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNTB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 397.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CNTB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNTB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $42.6M market capitalization and -2384.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CNTB vs PYPD Key Questions & Quantitative Answers

As of Nov 17, 2026, Connect Biopharma Holdings Limited (CNTB) is the stronger overall head-to-head candidate over PolyPid Ltd. (PYPD) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNTB carries a Unified Composite Score of 41.0/100 (SELL) at $0.61 (0.8x Forward P/E, -2384.5% operating margin), whereas PYPD carries 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although CNTB compares more favorably head-to-head, both CNTB (41.0/100 SELL) and PYPD (31.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 65.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with PYPD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CNTB generates $3.0M in USD-normalized revenue versus N/A for PYPD. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PYPD.

CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus PYPD (-243.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.